Vitamin D status and breast cancer in Saudi Arabian women: case-control study

Yousef, Fatimah M; Jacobs, Elizabeth T.; Kang, Paul; Hakim, Iman A.; Going, Scott B.; Yousef, Jehad M.; Al‐Raddadi, Rajaa; Kumosani, Taha; Thomson, Cynthia A.

doi:10.3945/ajcn.112.054445

Cited by 41 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With a mean of 17.8 ng/mL of serum vitamin D in the breast cancer patients as compared to the mean of 25.9 ng/ mL in healthy controls, the present study shows agreement with previous studies in Saudi Arabia [11] and in other parts of the world. [2,3,4] The present study also shows that levels of vitamin D in triple negative breast cancer with mean of 13.3ng/mL is lowest among all the subtypes.…”

Section: Discussionsupporting

confidence: 92%

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Goyal

Garg²

2017

APALM

View full text Add to dashboard Cite

Background: Vitamin D deficiency has been associated with poor prognosis in breast cancer. A new molecular classification of breast cancer is being increasingly used that is based on expression of estrogen receptors, progesterone receptors and Her2/neu amplification and is found to correlate well with prognosis and outcome of disease. The present study was designed to determine serum vitamin D deficiency in these molecular subtypes of breast cancer. Methods:Estimation ofserum vitamin D levels by chemiluminiscence was done in a cohort of 99 breast cancer patients and 25 age matched healthy controls. Breast cancer patients were further grouped into luminal A, luminal B, Her2/neu enriched and triple negative subtypes based on immunohistochemistry results. Non-parametric tests were performed to compare vitamin D levels in different groups.Results: 54.6%, 60%, 66.6% and 84.2% of patients with luminal A, luminal B, Her2/neu enriched and triple negative subtypes respectively were found to be vitamin D deficient (<20ng/mL) as compared to only 20% in healthy controls. More aggressive Her2/neu enriched and triple negative subtype patients had significantly lower serum vitamin D levels than the luminal subtypes of breast cancer. Conclusion:Vitamin D deficiency is more prevalent and significantly lower levels are found in more aggressive subtypes of breast cancer. Vitamin D supplementation must be considered in these forms of breast cancer to improve outcome.

show abstract

Section: Discussionsupporting

confidence: 92%

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Goyal

Garg²

2017

APALM

View full text Add to dashboard Cite

show abstract

“…A protective effect of vitamin D against breast cancer has been suggested in several studies [1e3], which has been related to sunlight [4], dietary intake [5], vitamin D supplement [6e8], and ethnic background [9,10]. Studies regarding the association between serum 25-hydroxyvitamin D (25OHD) and breast cancer risk [11,12] have, however, not been conclusive.…”

Section: Introductionmentioning

confidence: 99%

Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case–control study

et al. 2016

View full text Add to dashboard Cite

“…It is well known that vitamin D 3 regulate the level of phosphorus and calcium in the blood by participating in the process of mineral metabolism and bone growth and this was confirmed by the results in (Table 1-3). In the absence of vitamin D 3 , calcium and phosphorus does not absorbed with high efficiency (Calvo and Uribarri, 2013;Yousef et al, 2013) and thus withdrawn from the bones into the blood and this may not seen clearly in the blood and this is what shown in the (Table 1-4) and as a result increase the level of the enzyme alkaline phosphatase which is one of the most important clinical biochemical indicators of osteoporosis (Gonzlez-Perez et al, 2011). This study showed that osteoporosis may increases the incidence of uterine cancer.…”

Section: Discussionmentioning

confidence: 79%

Osteoporosis as a Novel Marker of Uterine Cancer Risk Factor

Al-Jawadi¹

2014

American Journal of Applied Sciences

View full text Add to dashboard Cite

Due to limited available information on the occurrence and treatment of uterine cancer, health institutions in major countries trend to study some factors and diseases that may relation or plays as predisposing factors of the occurrence of uterine cancer and the lack of previous studies on the impact of osteoporosis on the incidence of uterine cancer and the rapid spread of uterine cancer in recent years all over the world and till know the exact mechanism is not fully clear. This study focused on the following: Possibility of osteoporosis as a marker of uterine cancer by studying the relationship between osteoporosis and uterine cancer through a biochemical and hormonal parameters responsible for osteoporosis and its effect on uterus and possibility of malignant changes. The study included collection of samples attending the Hospitals in Mosul, from 82 women had no uterine cancer and divided to two groups (44 healthy women and 38 women diagnosed as osteoporosis only) and 101 women with uterine cancer (43 with uterine cancer only and 58 women are associated osteoporosis with uterine cancer dose not received any treatment for their condition). Each patient was evaluated clinically and by a biochemical laboratory tests, which include phosphorus, calcium, vitamin D 3 , alkaline phosphatase ALP, estrogen and progesterone in serum by using commercial kits. The results showed the osteoporosis may increases the incidence of uterine cancer. Novel of this research showed that Osteoporosis is a new risk factor for uterine cancer. Accordingly, women should pay attention for her bone health and early diagnosis and treatment of osteoporosis to prevent and reduce the risk of uterine cancer.

show abstract

Vitamin D status and breast cancer in Saudi Arabian women: case-control study

Abstract: An inverse association exists between serum 25(OH)D concentrations and breast cancer risk in Saudi Arabian women. This trial was registered at clinicaltrials.gov as NCT01817231.

Cited by 41 publications

References 43 publications

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case–control study

Osteoporosis as a Novel Marker of Uterine Cancer Risk Factor

Contact Info

Product

Resources

About